Sutro Biopharma Stocks List

Recent Signals

Date Stock Signal Type
2021-05-11 ANAB Upper Bollinger Band Walk Strength
2021-05-11 ANAB Slingshot Bullish Bullish Swing Setup
2021-05-11 APVO Lower Bollinger Band Walk Weakness
2021-05-11 BTAI Wide Range Bar Range Expansion
2021-05-11 BTAI Lower Bollinger Band Walk Weakness
2021-05-11 BTAI Slingshot Bearish Bearish Swing Setup
2021-05-11 BTAI Pocket Pivot Bullish Swing Setup
2021-05-11 BTAI MACD Bullish Signal Line Cross Bullish
2021-05-11 BTAI 20 DMA Resistance Bearish
2021-05-11 BTAI New 52 Week Low Weakness
2021-05-11 CTMX 50 DMA Resistance Bearish
2021-05-11 EQ Stochastic Reached Oversold Weakness
2021-05-11 KRBP Lower Bollinger Band Walk Weakness
2021-05-11 KRBP New 52 Week Low Weakness
2021-05-11 KRBP NR7 Range Contraction
2021-05-11 KRBP Narrow Range Bar Range Contraction
2021-05-11 KRBP New 52 Week Closing Low Bearish
2021-05-11 MDNA Calm After Storm Range Contraction
2021-05-11 MDNA NR7 Range Contraction
2021-05-11 PCVX Lower Bollinger Band Walk Weakness
2021-05-11 PCVX New 52 Week Low Weakness
2021-05-11 STRO Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-05-11 STRO Pocket Pivot Bullish Swing Setup
2021-05-11 STRO Bollinger Band Squeeze Range Contraction
2021-05-11 STRO 20 DMA Support Bullish

Recent News for Sutro Biopharma Stocks

Date Stock Title
May 11 PCVX Vaxcyte EPS beats by $0.10
May 11 PCVX Vaxcyte Reports First Quarter 2021 Financial Results and Provides Business Update
May 11 APVO Aptevo Therapeutics EPS misses by $0.12, misses on revenue
May 11 APVO Aptevo Therapeutics Reports First Quarter 2021 Financial Results
May 11 BTAI BioXcel Therapeutics Announces Presentations at the ISBD 2021 Global Annual Conference
May 10 BTAI BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q1 2021 Results - Earnings Call Transcript
May 10 PCVX Vaxcyte Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease
May 10 BTAI BioXcel Therapeutics EPS misses by $0.14
May 10 BTAI BioXcel Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 9 CTMX CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q1 2021 Results - Earnings Call Transcript
May 9 BTAI The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 9 ANAB Forecast: Analysts Think AnaptysBio, Inc.'s (NASDAQ:ANAB) Business Prospects Have Improved Drastically
May 8 CTMX CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript
May 8 ANAB The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More
May 7 MDNA Medicenna's MDNA55 Data From Mid-Stage Brain Cancer Study Published In Peer-Reviewed Clinical Cancer Research
May 7 MDNA Medicenna posts positive data from mid-stage brain cancer study
May 7 MDNA Medicenna Announces the Peer-Reviewed Publication of Clinical Data from Phase 2b Trial Evaluating MDNA55 in Recurrent Glioblastoma
May 7 STRO Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates
May 7 STRO Sutro Biopharma EPS misses by $0.04, beats on revenue
May 7 STRO Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
Related Industries: Biotechnology

Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California, featuring clinical-stage drug discovery, development andmanufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is advancing next-generation oncology therapeutics through precision protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. The current CEO, William Newell, joined Sutro in January 2009. Mr. Newell has over 20 years of senior management experience in the biotechnology industry, and has worked for companies such as Aerovance, QLT, Inc., and Axys Pharmaceuticals, Inc. The CSO, Trevor Hallam, formerly worked at Palatin Technologies, AstraZeneca, SmithKline & French, Glaxo Group Research, and Roche Research Centre and Rhone-Poulenc Rorer. The CMO, Arturo Molina is a medical oncologist, who was most recently with J&J Innovation and was formerly with Cougar, Biogen Idec and the City of Hope Comprehensive Cancer Center. Shabbir Anik is the Chief Technical Operations Officer, formerly withOnyx/Amgen,Althea, Patheon, Neurex and Syntex.
The company has raised over $275m from Venture Investors, Collaborators and the Public Markets.
Sutro’s proprietary and integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+™, led to the discovery of STRO-001 and STRO-002, Sutro’s first two internally-developed antibody drugconjugates, or ADCs. STRO-001 is a potentially first-in-class ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin’s lymphoma, and is currently in a Phase I clinical trial. STRO-002 is a potentially best-in-class ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Sutro expects to commence a STRO-002 Phase 1 clinical trial focused on ovarian and endometrial cancers in early 2019.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need.
To date, Sutro’s drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Sutro’s platform allows it to accelerate discovery and development of potential first-in-class and best-in-class molecules through rapid and systematic evaluation of protein structure-activity relationships to create optimized homogeneous product candidates.
In addition to developing its own oncology pipeline, Sutro is collaborating with select pharmaceutical and biotech companies to discover and develop novel, next generationtherapeutics. As the pace of clinical development accelerates, Sutro and its partners are developing therapeutics designed to more efficiently kill tumors without harming healthy cells.

More about Sutro Biopharma
Browse All Tags